Oppenheimer Asset Management’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $63.7M | Buy |
69,246
+7,044
| +11% | +$7.14M | 0.73% | 21 |
|
|
2025
Q4 | $66.8M | Sell |
62,202
-3,314
| -5% | -$3.17M | 0.82% | 19 |
|
|
2025
Q3 | $50M | Sell |
65,516
-2,775
| -4% | -$2.07M | 0.55% | 32 |
|
|
2025
Q2 | $53.2M | Sell |
68,291
-9,991
| -13% | -$7.76M | 0.61% | 28 |
|
|
2025
Q1 | $64.7M | Buy |
78,282
+16,442
| +27% | +$13.7M | 0.8% | 17 |
|
|
2024
Q4 | $47.7M | Buy |
61,840
+22,577
| +58% | +$18.7M | 0.58% | 27 |
|
|
2024
Q3 | $34.8M | Sell |
39,263
-127
| -0.3% | -$114K | 0.42% | 50 |
|
|
2024
Q2 | $35.7M | Buy |
39,390
+3,151
| +9% | +$2.52M | 0.46% | 44 |
|
|
2024
Q1 | $28.2M | Sell |
36,239
-3,993
| -10% | -$2.84M | 0.41% | 48 |
|
|
2023
Q4 | $23.5M | Sell |
40,232
-168
| -0.4% | -$98.1K | 0.33% | 66 |
|
|
2023
Q3 | $21.7M | Sell |
40,400
-2,114
| -5% | -$1.09M | 0.33% | 61 |
|
|
2023
Q2 | $19.9M | Sell |
42,514
-822
| -2% | -$345K | 0.29% | 71 |
|
|
2023
Q1 | $14.9M | Buy |
43,336
+1,417
| +3% | +$478K | 0.23% | 111 |
|
|
2022
Q4 | $15.3M | Sell |
41,919
-1,001
| -2% | -$355K | 0.25% | 99 |
|
|
2022
Q3 | $13.9M | Sell |
42,920
-22,455
| -34% | -$7.11M | 0.24% | 100 |
|
|
2022
Q2 | $21.2M | Sell |
65,375
-22,129
| -25% | -$6.64M | 0.36% | 63 |
|
|
2022
Q1 | $25.1M | Buy |
87,504
+16,051
| +22% | +$4.13M | 0.36% | 63 |
|
|
2021
Q4 | $19.7M | Sell |
71,453
-776
| -1% | -$197K | 0.26% | 93 |
|
|
2021
Q3 | $16.7M | Sell |
72,229
-16,561
| -19% | -$4.09M | 0.24% | 96 |
|
|
2021
Q2 | $20.4M | Buy |
88,790
+4,988
| +6% | +$1M | 0.29% | 77 |
|
|
2021
Q1 | $15.7M | Sell |
83,802
-17,791
| -18% | -$3.48M | 0.24% | 98 |
|
|
2020
Q4 | $17.2M | Sell |
101,593
-4,996
| -5% | -$746K | 0.29% | 82 |
|
|
2020
Q3 | $15.8M | Sell |
106,589
-25,121
| -19% | -$3.89M | 0.31% | 76 |
|
|
2020
Q2 | $21.6M | Sell |
131,710
-55,009
| -29% | -$8.44M | 0.45% | 49 |
|
|
2020
Q1 | $25.9M | Sell |
186,719
-7,774
| -4% | -$1.07M | 0.64% | 32 |
|
|
2019
Q4 | $25.6M | Sell |
194,493
-35,624
| -15% | -$4.13M | 0.54% | 28 |
|
|
2019
Q3 | $25.7M | Sell |
230,117
-7,398
| -3% | -$824K | 0.57% | 24 |
|
|
2019
Q2 | $26.3M | Sell |
237,515
-8,818
| -4% | -$1.04M | 0.58% | 23 |
|
|
2019
Q1 | $32M | Sell |
246,333
-59,605
| -19% | -$7.25M | 0.72% | 18 |
|
|
2018
Q4 | $35.4M | Sell |
305,938
-2,016
| -0.7% | -$225K | 0.88% | 16 |
|
|
2018
Q3 | $33M | Buy |
307,954
+6,655
| +2% | +$665K | 0.73% | 15 |
|
|
2018
Q2 | $25.7M | Sell |
301,299
-17,897
| -6% | -$1.47M | 0.63% | 23 |
|
|
2018
Q1 | $24.7M | Buy |
319,196
+4,602
| +1% | +$370K | 0.62% | 23 |
|
|
2017
Q4 | $26.9M | Hold |
314,594
| – | – | 0.71% | 19 |
|
|
2017
Q3 | $26.9M | Sell |
314,594
-14,374
| -4% | -$1.18M | 0.7% | 20 |
|
|
2017
Q2 | $27.1M | Buy |
328,968
+5,192
| +2% | +$424K | 0.75% | 16 |
|
|
2017
Q1 | $27.2M | Buy |
+323,776
| New | +$25.9M | 0.78% | 16 |
|
Other funds holding LLY
VCM
VPM
Oppenheimer Asset Management's LLY Position: Q1 2026 in Review
Oppenheimer Asset Management increased its Eli Lilly (LLY) stake by 11% in Q1 2026, buying an estimated $7.14M and bringing the position to 69,246 shares worth $63.7M. The position accounts for 0.73% of the portfolio, ranked #21.
Oppenheimer Asset Management first reported a position in LLY in Q1 2017 and has held it in 37 quarters since. The position peaked at $66.8M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Oppenheimer Asset Management held 69,246 shares of Eli Lilly worth $63.7M as of Q1 2026.
- Oppenheimer Asset Management bought 7,044 Eli Lilly shares in Q1 2026, an estimated $7.14M.
- Eli Lilly made up 0.73% of Oppenheimer Asset Management's portfolio in Q1 2026, its #21 holding.
- Oppenheimer Asset Management first reported a position in Eli Lilly in Q1 2017 and has held it in 37 quarters since.
- Oppenheimer Asset Management's Eli Lilly position peaked at $66.8M in Q4 2025.
- 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Oppenheimer Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.